In a prospective, randomized trial, norfloxacin (400 mg perorally, twice a day) was compared with trimethoprim-sulfamethoxazole (160-800 mg perorally, twice a day) in 45 patients with uncomplicated urinary tract infections. Escherichia coi was the most common isolate. Infections due to Enterobacter spp., Proteus mirabilis, Pseudomonas spp., and Staphylococcus spp. were also treated. Norfloxacin was equivalent in effectiveness and safety to trimethoprim-sulfamethoxazole, with a cure rate of 91% at the 5-to 9-day posttherapy visit and 88% at the 4-to 6-week posttherapy visit. It was well tolerated and had a low incidence of side effects.
Norfloxacin, a new orally absorbed quinilone antibiotic, is related to nalidixic acid, but has a broader spectrum of activity that includes Staphylococcus saprophyticus, enterococci, Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa, including aminoglycoside-resistant strains (4, 8, 9) . Resistance to norfloxacin does not develop as readily as previously reported to occur with nalidixic acid (4, 8, 9) . Urinary concentrations of approximately 30 to 150 ,ug/ml are found 8 to 10 h after a single 400-mg oral dose, allowing twice-daily dosage (1, 3, 5, 13 Although SXT is frequently prescribed for urinary tract infection, a number of patients will have resistant isolates or give a history of allergy or adverse reaction to sulfonamides (12, (14) (15) (16) . Our study showed that norfloxacin was clinically and microbiologically as effective as SXT in the therapy of uncomplicated, community-acquired urinary tract infections. Cure was achieved in 91% of norfloxacin-treated patients at the 5-to 9-day posttherapy visit, and 88% continued to be asymptomatic and have negative urine cultures 4 to 6 weeks posttherapy. European studies (2, 6, 7, 10, 14) showed similar results, but several were either uncontrolled or gave sparse methodology. Clinical side effects (nausea, headache, insomnia) were seen in 23% of the SXT group and 14% of the norfloxacin group. None of these adverse reactions was serious in nature. Most of our patients had infections with susceptible E. coli. Further clinical trials should be conducted to determine the effectiveness of norfloxacin in patients with complicated urinary tract infections and those with antibiotic-resistant bacteria.
